Cancer Causes & Control

, Volume 27, Issue 11, pp 1371–1379 | Cite as

Single and multiple high-risk and low-risk Human Papillomavirus association with cervical lesions of 11,224 women in Jakarta

  • Lydia S. Murdiyarso
  • Melissa Kartawinata
  • Iffat Jenie
  • Grace Widjajahakim
  • Heriawaty Hidajat
  • Ruth Sembiring
  • I. Made Nasar
  • Santoso Cornain
  • Farid Sastranagara
  • Ahmad Rusdan Handoyo Utomo
Original paper

Abstract

Purpose

We sought to evaluate prevalence, age-adjusted distribution, and impact of single and multiple high- and low-risk human papillomavirus (HPV) subtypes and their associations with cervical lesions.

Methods

Data were extracted from 11,224 women who underwent routine screening of HPV genotyping and liquid-based cytology co-testing. Fifteen high-risk (HR) and six low-risk (LR) HPV types were genotyped.

Results

Overall HPV prevalence was 10.7 %, and young women (under 21 years old) harbored highest HPV infection rate (40.38 %). The rate declined in old women 9.49 % (age 30–49) and 6.89 % (age 50 and above). Normal cytology had lowest HPV (5.66 %) compared to low-grade (60.49 %), high-grade (71.96 %) squamous intraepithelial lesions (LSIL and HSIL) and squamous cell carcinoma SCC (86.9 %). LR HPV subtypes were absent in SCC and were consistently lower than HR HPV in LSIL (6.74 vs. 33.54 %) and HSIL (2.12 vs. 51.32 %). Multiple HPV infection was more frequent in young women under 30 years old (10 %) than older women (2 %) and in LSIL (20.2 %), HSIL (18.5 %) than SCC (4.4 %). HR HPV 52, 16, 18, and 58 were the most frequent subtypes in normal, LSIL, and HSIL. Greater or equal proportion of HPV 16, 18, 45, and 52 was found in SCC compared to normal cytology (SCC/normal ratios 4.8, 1.2, 1.6, and 1.7). While important in LSIL and HSIL, HPV58 was not detected in SCC.

Conclusion

Taken together, identification of these HPV types, especially HPV 16, 18, 45, and 52, and their associated cervical lesions may improve cervical cancer preventive strategies in Indonesia.

Keywords

HPV LBC HSIL LSIL Cervical cancer Genotyping Indonesia High-risk HPV Low-risk HPV Screening 

Notes

Acknowledgments

Funding was provided to Stem Cell and Cancer Institute by Kalbe Farma (Internal Research Grant). We thanked Sartika Sari, Gunawan, Apryanti Masniary, Lusiana Mutiara, Shirliey Foo, Audi Tri Harsono and Yudhi Nugraha S. Putra for their excellent technical assistance, also Dr. Yong Wee Wong (DNA Laboratories Sdn Bhd, Malaysia) for the technical collaborations.

References

  1. 1.
    Safaeian M, Rodriguez AC (2014) Invited commentary: multiple human papillomavirus infections and type replacement—anticipating the future after human papillomavirus vaccination. Am J Epidemiol 180:1076–1081. doi:10.1093/aje/kwu265 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Hausen zur h (2002) Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2:342–350. doi:10.1038/nrc798 CrossRefGoogle Scholar
  3. 3.
    Schiffman M, Wentzensen N (2013) Human papillomavirus infection and the multistage carcinogenesis of cervical cancer. Cancer Epidemiol Biomark Prev 22:553–560. doi:10.1158/1055-9965.EPI-12-1406 CrossRefGoogle Scholar
  4. 4.
    Trottier H (2006) Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol Biomark Prev 15:1274–1280. doi:10.1158/1055-9965.EPI-06-0129 CrossRefGoogle Scholar
  5. 5.
    Dickson EL, Vogel RI, Geller MA, Downs LS Jr (2014) Cervical cytology and multiple type HPV infection: a study of 8182 women ages 31–65. Gynecol Oncol 133:405–408. doi:10.1016/j.ygyno.2014.03.552 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Chagas BS, Comar M, Gurgel APAD et al (2015) Association study between cervical lesions and single or multiple vaccine-target and non-vaccine target human papillomavirus (HPV) types in women from northeastern Brazil. PLoS One 10:e0132570. doi:10.1371/journal.pone.0132570 CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Wentzensen N, Nason M, Schiffman M et al (2014) No evidence for synergy between human papillomavirus genotypes for the risk of high-grade squamous intraepithelial lesions in a large population-based study. J Infect Dis 209:855–864. doi:10.1093/infdis/jit577 CrossRefPubMedGoogle Scholar
  8. 8.
    Liu SS, Leung R, Chan K (2010) Evaluation of a newly developed GenoArray human papillomavirus (HPV) genotyping assay and comparison with the Roche Linear Array HPV genotyping assay. J Clin 48:758–764. doi:10.1128/JCM.00989-09 Google Scholar
  9. 9.
    Yang Z, Cuzick J, Hunt WC, Wheeler CM (2014) Concurrence of multiple human papillomavirus infections in a large US population-based cohort. Am J Epidemiol 180:1066–1075. doi:10.1093/aje/kwu267 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Goodman A (2015) HPV testing as a screen for cervical cancer. BMJ 350:h2372. doi:10.1136/bmj.h2372 CrossRefPubMedGoogle Scholar
  11. 11.
    Blatt AJ, Kennedy R, Luff RD et al (2015) Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices. Cancer Cytopathol 123:282–288. doi:10.1002/cncy.21544 CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Hosaka M, Fujita H, Hanley SJ et al (2012) Incidence risk of cervical intraepithelial neoplasia 3 or more severe lesions is a function of human papillomavirus genotypes and severity of cytological and histological abnormalities in adult Japanese women. Int J Cancer 132:327–334. doi:10.1002/ijc.27680 CrossRefPubMedGoogle Scholar
  13. 13.
    Cuschieri KS (2005) Persistent high risk HPV infection associated with development of cervical neoplasia in a prospective population study. J Clin Pathol 58:946–950. doi:10.1136/jcp.2004.022863 CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Chen H-C, Schiffman M, Lin C-Y et al (2011) Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer. J Natl Cancer Inst 103:1387–1396. doi:10.1093/jnci/djr283 CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Bruni L, Barrionuevo-Rosas L, Albero G, Serrano B, Mena M, Gómez D, Muñoz J, Bosch FX, de Sanjosé S. ICO Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in Indonesia. Summary Report 7 October 2016. Accessed 12 Oct 2016Google Scholar
  16. 16.
    Schellekens MC, Dijkman A, Aziz MF et al (2004) Prevalence of single and multiple HPV types in cervical carcinomas in Jakarta, Indonesia. Gynecol Oncol 93:49–53. doi:10.1016/j.ygyno.2003.12.015 CrossRefPubMedGoogle Scholar
  17. 17.
    Panigoro R, Susanto H, Novel SS et al (2013) HPV genotyping linear assay test comparison in cervical cancer patients: implications for HPV prevalence and molecular epidemiology in a limited-resource area in Bandung, Indonesia. Asian Pac J Cancer Prev 14:5843–5847. doi:10.7314/APJCP.2013.14.10.5843 CrossRefPubMedGoogle Scholar
  18. 18.
    Vet JNI, de Boer MA, van den Akker BEWM et al (2008) Prevalence of human papillomavirus in Indonesia: a population-based study in three regions. Br J Cancer 99:214–218. doi:10.1038/sj.bjc.6604417 CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Wheeler CM, Hunt WC, Cuzick J et al (2012) A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination. Int J Cancer 132:198–207. doi:10.1002/ijc.27608 CrossRefPubMedGoogle Scholar
  20. 20.
    Clifford GM, Rana RK, Franceschi S et al (2005) Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomark Prev 14:1157–1164. doi:10.1158/1055-9965.EPI-04-0812 CrossRefGoogle Scholar
  21. 21.
    Clifford GM, Smith JS, Aguado T, Franceschi S (2003) Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 89:101–105. doi:10.1038/sj.bjc.6601024 CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Guan P, Howell-Jones R, Li N et al (2012) Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer 131:2349–2359. doi:10.1002/ijc.27485 CrossRefPubMedGoogle Scholar
  23. 23.
    Smith JS, Lindsay L, Hoots B et al (2007) Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 121:621–632. doi:10.1002/ijc.22527 CrossRefPubMedGoogle Scholar
  24. 24.
    Bao YP, Li N, Smith JS, Qiao YL (2008) Human papillomavirus type distribution in women from Asia: a meta-analysis. Int J Gynecol Cancer 18:71–79. doi:10.1111/j.1525-1438.2007.00959.x CrossRefPubMedGoogle Scholar
  25. 25.
    Liu X-X, Fan X-L, Yu Y-P et al (2014) Human papillomavirus prevalence and type-distribution among women in Zhejiang Province, Southeast China: a cross-sectional study. BMC Infect Dis 14:708. doi:10.1186/s12879-014-0708-8 CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Wei H, Wang N, Zhang Y et al (2014) Distribution of various types of low-risk human papillomavirus according to cervical cytology and histology in northern Chinese women. Int J Gynaecol Obstet 126:28–32. doi:10.1016/j.ijgo.2014.01.020 CrossRefPubMedGoogle Scholar
  27. 27.
    Bruni L, Diaz M, Castellsagué X et al (2010) Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 202:1789–1799. doi:10.1086/657321 CrossRefPubMedGoogle Scholar
  28. 28.
    Li N, Franceschi S, Howell-Jones R et al (2010) Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer 128:927–935. doi:10.1002/ijc.25396 CrossRefGoogle Scholar
  29. 29.
    Katki HA, Schiffman M, Castle PE et al (2013) Benchmarking CIN3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines. J Lower Genit Tract Dis 17:S28–S35. doi:10.1097/LGT.0b013e318285423c CrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Lydia S. Murdiyarso
    • 1
  • Melissa Kartawinata
    • 1
  • Iffat Jenie
    • 1
  • Grace Widjajahakim
    • 1
  • Heriawaty Hidajat
    • 3
  • Ruth Sembiring
    • 3
  • I. Made Nasar
    • 1
  • Santoso Cornain
    • 4
  • Farid Sastranagara
    • 1
  • Ahmad Rusdan Handoyo Utomo
    • 1
    • 2
  1. 1.Kalbe Genomics LaboratoryJakartaIndonesia
  2. 2.Stem Cell and Cancer InstitutePT Kalbe FarmaJakartaIndonesia
  3. 3.Rumah Sakit PersahabatanRawamangun, JakartaIndonesia
  4. 4.Faculty of Medicine University of IndonesiaJakartaIndonesia

Personalised recommendations